

LETTER TO THE EDITOR

Open Access



Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer

Yao Zhan^{1†}, Lutao Du^{1,2†}, Lishui Wang³, Xiumei Jiang¹, Shujun Zhang¹, Juan Li¹, Keqiang Yan⁴, Weili Duan¹, Yinghui Zhao¹, Lili Wang³, Yunshan Wang¹ and Chuanxin Wang^{1,2*}

Abstract

Recently, expression signatures of exosomal long non-coding RNAs (lncRNAs) have been proposed as potential non-invasive biomarkers for cancer detection. In this study, we aimed to develop a urinary exosome (UE)-derived lncRNA panel for diagnosis and recurrence prediction of bladder cancer (BC). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to screen and evaluate the expressions of eight candidate lncRNAs in a training set (208 urine samples) and a validation set (160 urine samples). A panel consisting of three differently expressed lncRNAs (MALAT1, PCAT-1 and SPRY4-IT1) was established for BC diagnosis in the training set, showing an area under the receiver-operating characteristic (ROC) curve (AUC) of 0.854. Subsequently, the performance of the panel was further verified with an AUC of 0.813 in the validation set, which was significantly higher than that of urine cytology (0.619). In addition, Kaplan-Meier analysis suggested that the up-regulation of PCAT-1 and MALAT1 was associated with poor recurrence-free survival (RFS) of non-muscle-invasive BC (NMIBC) ($p < 0.001$ and $p = 0.002$, respectively), and multivariate Cox proportional hazards regression analysis revealed that exosomal PCAT-1 overexpression was an independent prognostic factor for the RFS of NMIBC ($p = 0.018$). Collectively, our findings indicated that UE-derived lncRNAs possessed considerable clinical value in the diagnosis and prognosis of BC.

Keywords: Bladder cancer, Urine exosomes, LncRNA, Non-invasive biomarkers, Diagnosis, Recurrence prediction

Bladder cancer (BC) is the most common malignancy of the urinary tract worldwide [1]. About 75% of patients are classified as non-muscle-invasive BC (NMIBC), which features a high recurrence rate. Moreover, roughly half of the muscle invasive BC (MIBC) patients will progress to metastasis and die within 3 years [2]. The poor prognosis of BC is partially due to lack of an effective means for early diagnosis. At present, the diagnosis of BC mainly relies on cystoscopy. However, the invasiveness of such procedure limit its use in mass cancer screening. Urine cytology has been proved to be ineffective as a tool to detect low-grade

malignancy. Therefore, discovery of effective biomarkers for detection and recurrence prediction of BC can play pivotal roles in improving the prognosis of BC patients.

Exosomes are small vesicles with a diameter of approximately 30–150 nm. They are distributed in nearly all body fluids, including blood and urine. Exosomes can act as vehicles in cell-to-cell communication by transferring oncogenic molecules and play significant roles in tumorigenesis, progression and metastasis [3]. These functional contents are not stochastically packed into exosomes, which may rely on signature motifs, leading to the variation of exosomal contents under different pathological conditions or in different original cell types [4]. Studies have shown that BC cells can secrete exosomes into the urine and lncRNAs have been found to be stably present in exosomes [5]. Therefore, analyzing the expression profiles of urinary exosome (UE)-derived lncRNAs would provide valuable clues

* Correspondence: cwxwang@sdu.edu.cn

[†]Yao Zhan and Lutao Du contributed equally to this work.

¹Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan 250033, Shandong, China

²Tumor Marker Detection Engineering Laboratory of Shandong Province, Jinan, Shandong, China

Full list of author information is available at the end of the article



for diagnosis of BC. In this study, we systematically analyzed the expression profiles of UE-derived lncRNAs in BC patients and established a three-lncRNA panel for BC detection. Finally, we explored the prognostic value of the selected exosomal lncRNAs.

Results and discussion

Characterization of UEs

Transmission electron microscopy (TEM) showed UEs have a diameter of 60–150 nm with a cup-shaped membrane (Fig. 1a). Western blotting of UEs demonstrated the presence of CD9 and TSG101, which are exosome markers (Fig. 1b). Nanoparticle tracking analysis (NTA) found that particles ranging from 20 nm to 200 nm in diameter accounted for 98.1% (Fig. 1c). The flow cytometry showed that the positive rate of CD63 and CD81 specific antibodies on the exosome surface was 90.9% and 93.6%, respectively (Fig. 1d). Collectively, these data indicated that exosomes existed in urine, which laid a foundation for further study of exosomal biomarkers. The methods are explained in Additional file 1.

Selection and evaluation of candidate UE-derived lncRNAs in BC patients


Eight lncRNAs (MALAT1, PCAT-1, SPRY4-IT1, UCA1, MEG3, H19, UBC1 and TUG1), which have been reported to play functional roles in tumorigenesis, were selected as candidate molecules [6–8]. Then, in the training set, the expressions of eight lncRNAs in 104 BC patients and 104 healthy controls were assessed


by qRT-PCR. MALAT1, PCAT-1 and SPRY4-IT1 were significantly up-regulated in BC patients compared with the healthy controls ($p < 0.001$) (Additional file 3: Table S2) (Additional file 4: Figure S1 a-c).

To evaluate the performance of the identified lncRNAs for BC detection, we performed ROC curves in training set. The diagnostic accuracy of MALAT1, PCAT-1 and SPRY4-IT1, measured by AUC, was 0.844 (95% CI = 0.787 to 0.890, sensitivity = 72.1% and specificity = 84.6%), 0.832 (95% CI = 0.774 to 0.880, sensitivity = 72.1% and specificity = 81.7%) and 0.760 (95% CI = 0.696 to 0.817, sensitivity = 66.3% and specificity = 76.9%), respectively (Additional file 4: Figure S1 d-f). Subsequently, these lncRNAs were further verified in the validation set (80 BC patients and 80 healthy controls). The dysregulated expression trend was consistent between the two set (Additional file 3: Table S2). The corresponding AUCs of the three lncRNAs were 0.785 (95% CI = 0.714 to 0.846, sensitivity = 78.7% and specificity = 67.5%), 0.810 (95% CI = 0.741 to 0.868, sensitivity = 71.2% and specificity = 80.0%) and 0.799 (95% CI = 0.728 to 0.858, sensitivity = 87.5% and specificity = 65%), respectively (Additional file 5: Figure S2).

Analysis of the stability of identified lncRNAs in UEs

Next, two experiments were performed to verify the stability of UE-derived lncRNAs (MALAT1, PCAT-1 and SPRY4-IT1), considering that this is an essential prerequisite for biomarkers. Firstly, urine samples and exosome isolated nucleic acids were incubated with RNase A for 0, 30, 60 and 90 min. Strikingly, RNase A had no effect





on the level of exosomal lncRNAs in the urine group (Additional file 6: Figure S3 a-c). However, the exosome isolated nucleic acids group was completely degraded by the treatment of RNase A within 30 min (Additional file 6: Figure S3 d-f). Secondly, urine samples were stored at -80°C for 1, 2 and 3 months. Results indicated that this treatment had no effect on the expression levels of MALAT1, PCAT-1 and SPRY4IT1 in UEs (Additional file 6: Figure S3 g-i). Collectively, our data indicated that the exosomal membrane can protect lncRNAs from being degraded, and their excellent stability makes exosomal lncRNAs ideal biomarkers for tumor diagnosis.


Establishment of the UE-derived lncRNA panel for BC diagnosis

Considering that combinations of tumor markers can improve the diagnostic accuracy, multivariate logistic

regression model was performed in the training set to establish the selected exosomal lncRNA panel. The predictive probability of being diagnosed with BC was calculated using the equation as follows: $\text{Logit}(P) = 0.6577 - 0.0695 \times \text{MALAT1} - 0.0686 \times \text{PCAT-1} - 0.0015 \times \text{SPRY4-IT1}$. The AUC of the panel was 0.854 (95% CI = 0.799–0.899, sensitivity = 70.2% and specificity = 85.6%, Fig. 2a).

Validation of the diagnostic performance of the lncRNA panel

To further verify the diagnostic performance of the panel, ROC analysis was performed in the validation set. Results showed that the AUC of the panel was 0.813 (95% CI = 0.744–0.870, sensitivity = 62.5% and specificity = 85.0%) (Fig. 2b). Currently, urine cytology is widely used in clinical practice, but it has relatively poor sensitivity. Therefore, we compared the diagnostic performance



between the panel and urine cytology. As expected, the AUC of urine cytology for BC detection was 0.619 (95% CI =0.539–0.694, sensitivity = 25% and specificity = 98.7%) (Fig. 2c), which was significantly lower than that of the panel.

Correlation between the three UE-derived lncRNAs and clinicopathological characteristics

Next, we analyzed the correlation between the three UE-derived lncRNAs and clinicopathological characteristics of the BC patients. Results demonstrated overexpression of UE-derived PCAT-1 and SPRY4-IT1 were correlated with advanced TNM stage (all at $p < 0.05$). However, we did not find any significant association between the three lncRNAs and age, sex, tumor grade or positive lymph node metastasis (all at $p > 0.05$) (Additional file 7: Table S3).

Correlation between the three UE-derived lncRNAs and recurrence-free survival (RFS)

To explore prognostic value of the three lncRNAs, BC patients were followed-up in the validation set. In the NMIBC group, results showed that patients with up-regulated MALAT1 and PCAT-1 had a significantly lower RFS ($p = 0.002$ and $p < 0.001$, respectively, Fig. 3a-b) compared with their corresponding counterparts. Afterwards, univariate Cox proportional hazards regression showed that there was a significant correlation between RFS of NMIBC and PCAT-1 ($p = 0.001$), MALAT1 ($p = 0.005$) or tumor stage ($p = 0.001$). Multivariate analysis revealed that PCAT-1 ($p = 0.018$) and tumor stage ($p = 0.036$) were independent prognostic factors for the RFS of NMIBC (Additional file 8: Table S4). However, none of the three lncRNAs were correlated with the recurrence of MIBC patients (all at $p > 0.05$, Additional file 9: Table S5).

Researchers have revealed UE-derived HOTAIR could serve as a biomarker for BC. However, their study are only conducted in a very small amount of urine samples, which are not verified in a larger population [9]. Moreover, considering that the progression of BC is a complex pathophysiological process, thus no single lncRNA can stand alone as a biomarker, but instead panel consisting of several lncRNAs will be necessary for BC diagnosis.

Conclusions

We established a three-lncRNA panel for BC diagnosis through analyzing UE-derived lncRNAs, and identified that PCAT-1 could act as an independent risk factor for RFS of NMIBC. Further multi-center studies are necessary to verify the diagnostic efficiency of such panel before it could be adopted into clinical practice.

Additional files

Additional file 1: Materials and Methods (Additional file 2: Table S1 and Additional file 10). (DOCX 17 kb)

Additional file 2: Table S1. Characteristics of the study population in the training set and the validation set. (DOCX 17 kb)

Additional file 3: Table S2. Expression of selected UE-derived lncRNAs in BC patients and healthy controls. (DOCX 14 kb)

Additional file 4: Figure S1. Concentrations of UE-derived MALAT1, PCAT-1 and SPRY4-IT1 and their diagnostic performance for detection of BC. Concentrations of UE-derived MALAT1 (a), PCAT-1 (b) and SPRY4-IT1 (c) in BCs ($n = 104$) vs. healthy controls ($n = 104$) using qRT-PCR assay in the training set ($P < 0.001$). ROC curve analysis showing the diagnostic performance for BC of UE-derived MALAT1 (d), PCAT-1 (e) and SPRY4-IT1 (f) in the training set. *** represents $P < 0.001$. (TIF 512 kb)

Additional file 5: Figure S2. Validation of UE-derived MALAT1, PCAT-1 and SPRY4-IT1 as biomarkers for BC diagnosis and their diagnostic performance. Concentrations of UE-derived MALAT1 (a), PCAT-1 (b) and SPRY4-IT1 (c) in BCs ($n = 80$) vs. healthy controls ($n = 80$) using the qRT-PCR assay in the validation set ($P < 0.001$). ROC curve analysis showing the diagnostic performance for BC of UE-derived MALAT1 (d), PCAT-1 (e) and SPRY4-IT1 (f) in the validation set. *** represents $P < 0.001$. (TIF 431 kb)

Additional file 6: Figure S3. Stability of UEs. Urine group and exosome isolated nucleic acids group were incubated with RNase A for 0, 30, 60, and 90 min, respectively. RNase A had no effect on the level of exosomal lncRNAs in urine group (a-c). However, exosome isolated nucleic acids group were completely degraded by the treatment of RNase A within 30 min (d-f). Urine samples were incubated at -80°C for 1, 2, and 3 months, and this treatments had no effect on the level of exosomal lncRNAs (g-i). * represents $P < 0.05$, ** represents $P < 0.01$, *** represents $P < 0.001$. (TIF 1232 kb)

Additional file 7: Table S3. Correlation between concentrations of UE-derived lncRNAs and clinicopathological characteristics of BC patients in the validation set. (DOCX 15 kb)

Additional file 8: Table S4. Univariate and multivariate Cox proportional hazards regression model analysis for prediction of RFS in NMIBC from the validation set. (DOCX 14 kb)

Additional file 9: Table S5. Univariate Cox proportional hazards regression model analysis for prediction of RFS in MIBC from the validation set. (DOCX 13 kb)

Additional file 10: Primer sequences. (DOCX 14 kb)

Abbreviations

AUC: Area under the receiver-operating characteristic curve; BC: Bladder cancer; lncRNA: Long non-coding RNA; MIBC: Muscle invasive bladder cancer; NC: Negative controls; NMIBC: Non-muscle-invasive bladder cancer; NTA: Nanoparticle tracking analysis; qRT-PCR: Quantitative real time polymerase chain reaction; RFS: Recurrence-free survival; ROC: Receiver-operating characteristic; TEM: Transmission electron microscopy; TNM: Tumor-node metastasis; UE: Urinary exosome

Acknowledgements

We thank Dr. Chengjun Zhou (Department of Pathology, Second Hospital of Shandong University) and Dr. Junhui Zhen (Department of Pathology, Qilu Hospital of Shandong University) for their assistance in cytology and histology evaluations.

Funding

This study was supported by the National Natural Science Foundation of China (81501822, 81772271 and 81472025), Shandong Technological Development Project (2016CYJS01A02), The Science and Technology Development Plan Project of Jinan (201602154), Natural Science of Basic Scientific Research Foundation of Shandong University (2017BTS01) and Taishan Scholar Program of Shandong Province.

Availability of data and materials

The datasets used and/or analyzed during the current study are available within the manuscript and its supplementary information files.

Authors' contributions

YZ and LTD: performed experiments, analyzed data and drafted the manuscript; LTD, YSW and CXW: initiated, organized and supervised the study; LTD, LSW and XMJ: critically revised the manuscript; YZ, WLD and SJZ: collected urine samples; KQY: provide clinical information; LLW, JL, YHZ and WLD: provided technical support. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

This study was reviewed and approved by the Ethics Committee of Qilu Hospital of Shandong University, and all of the participants signed an informed consent form.

Consent for publication

All the patients involved in our study obtained written consent for publication.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan 250033, Shandong, China. ²Tumor Marker Detection Engineering Laboratory of Shandong Province, Jinan, Shandong, China. ³Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China. ⁴Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China.

Received: 19 June 2018 Accepted: 14 September 2018

Published online: 29 September 2018

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2018. *CA Cancer J Clin.* 2018; 68:7–30.
2. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. *Eur Urol.* 2017;71:447–61.
3. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. *J Hematol Oncol.* 2015;8:83.
4. Santangelo L, Giurato G, Cicchini C, Montaldo C, Mancone C, Tarallo R, et al. The RNA-binding protein SYNCRIP is a component of the hepatocyte exosomal machinery controlling microRNA sorting. *Cell Rep.* 2016;17:799–808.
5. Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. *J Urol.* 2014;192:583–92.
6. Liu L, Liu Y, Zhuang C, Xu W, Fu X, Lv Z, et al. Inducing cell growth arrest and apoptosis by silencing long non-coding RNA PCAT-1 in human bladder cancer. *Tumour Biol.* 2015;36:7685–9.
7. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. TGF- β -induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. *Clin Cancer Res.* 2014;20:1531–41.
8. Liu D, Li Y, Luo G, Xiao X, Tao D, Wu X, et al. LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. *Cancer Lett.* 2017;388:281–91.
9. Berrondo C, Flax J, Kucherov V, Siebert A, Osinski T, Rosenberg A, et al. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. *PLoS One.* 2016;11:e0147236.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

